Drug and Biomarkers
TIGER Clinical studies
The TIGER project
TIGER will advance the development of an intravenous (IV) platform technology that uses proprietary lipid nanoparticles (LNP) for a new class of mRNA-therapeutics with the potential to revolutionise care for patients with hard-to-treat cancers.
Successful clinical development should deliver an innovative affordable new therapy that yields a significant improvement on the current therapeutic approach and standard of care for all patients suffering from HPV16-related cancers. A phase 1/2a clinical study will deliver the clinical evidence to define the most appropriate strategy to advance into pivotal phase 2b/3 studies bring the therapy closer to market.
The project also advances exciting and innovative biomedical diagnostics to provide new tools to support later stage clinical studies, future oncology therapy development and patient stratification. Since our IV mRNA cancer vaccine platform can use virtually any antigen, any type of cancer could be targeted with the right antigens. This project will enable further application of the technology in a wide range of cancers using other tumour antigens.
Our project video is also available to watch in French, German, Dutch and Flemish.
JUNE is CANCER IMMUNOTHERAPY AWARENESS month To help raise awareness of mRNA based therapies the TIGER project are launching our simple explainer video available in 5 languages introducing this exciting new therapy for HPV16+ cancers....